Early treatment with Ocrevus may help protect the cerebellum from damage in people with multiple sclerosis, a study found.

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

and the FENtrepid trial in primary progressive MS, pitting it against Roche's antibody therapy Ocrevus (ocrelizumab). The drugmaker reported results from the main FENopta trial last year.

Ocrevus (ocrelizumab) offers a new treatment option for patients with relapsing disease. It is also the first drug approved for patients with primary progressive MS (PPMS), where symptoms get ...

Dr. Stephen Hauser was a young resident at Harvard when he met his first patient with multiple sclerosis, a woman with a thriving professional life who’d been completely wiped out by her condition, ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

A list of downloadable documents created during development.

Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq) is a prescription drug that’s used to treat certain forms of multiple sclerosis (MS). Ocrevus Zunovo comes as a ...

Primary progressive aphasia is a neurological condition that causes a gradual decline in language abilities. There is no cure or medication that can reverse or stop the progression of PPA.

The goal of the study was to validate MindGlide using 14,952 images from 1001 patients drawn from two clinical trials in primary and secondary progressive MS, as well as a routine-care MS dataset.